Literature DB >> 6204297

Response of an abnormal sinus node to intravenous flecainide acetate.

K J Hellestrand, A W Nathan, R S Bexton, A J Camm.   

Abstract

A patient with sinus node disease underwent provocative testing with flecainide, a new Vaughan Williams class IC antiarrhythmic agent. There were dramatic increases in sinus node recovery times and in sinoatrial conduction times, and the magnitude of the response could only be witnessed because of the emergence of a subsidiary junctional pacemaker without retrograde conduction to the atria.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6204297     DOI: 10.1111/j.1540-8159.1984.tb04928.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  4 in total

Review 1.  Safety of flecainide.

Authors:  Juan Tamargo; Alessandro Capucci; Philippe Mabo
Journal:  Drug Saf       Date:  2012-04-01       Impact factor: 5.606

Review 2.  Sinus node disease. Current concepts in diagnosis and therapy.

Authors:  J F Sneddon; A J Camm
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 3.  Drug effects on the sinus node. A clinical perspective.

Authors:  N J Linker; A J Camm
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

Review 4.  Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide.

Authors:  Juan Tamargo; Jean-Yves Le Heuzey; Phillipe Mabo
Journal:  Eur J Clin Pharmacol       Date:  2015-04-15       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.